IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
fixed rate dol lar terms. Blopress Comp was Takeda’s num ber nine in ter na tional phar ma ceu ti cal prod uct,
mak ing up 1.3% of cor po rate sales, up 7% in fixed rate dol lar terms. Blopress was Ja pan’s lead ing prod -
uct in 2008 ac cord ing to IMS and Takeda is de vel op ing a num ber of extended formulations and
indications.
Do mes tic sales of Leuplin were Yen66.4 bil lion, up 3.3%, while to tal global sales reached Yen124.0 bil lion
(down 2.7%). In the 12-month pe riod to the end of Sep tem ber 2008, ac cord ing to IMS, Enantone was
Takeda’s num ber four in ter na tional phar ma ceu ti cal prod uct, gen er at ing 6.3% of cor po rate sales, up 1%
over the pre vi ous year in fixed rate dol lar terms.. De spite Lupron hav ing faced pat ent ex piry in 2004, the
prod uct is still one of Takeda’s larg est. Lupron is rel a tively im mune to ge neric com pe ti tion, since it is a
ther a peu tic pro tein and the USA has yet to im ple ment a reg u la tory path way for ge neric biologics. Even in
Eu rope, which is more ad vanced on the way to reg u la tory ap proval for biosimilars, biologics of fer sig nif i -
cant im mu nity to ge neric com pe ti tion. Abbott gained rights to this product following the dissolution of the
TAP jv in mid-2008.
A 5.2% de cline in sales of Basen (voglibose) to Yen52.8 bil lion was re corded due to the en try of generics
and other un fa vor able fac tors. In the 12-month pe riod to the end of Sep tem ber 2008, Basen was
Takeda’s num ber five in ter na tional phar ma ceu ti cal prod uct, mak ing up 3.1% of cor po rate sales, with
sales down 6% in fixed rate dol lar terms, according to IMS.
Mil len nium pro vides a huge boost to Takeda’s on col ogy pipe line with a num ber of prom is ing can di dates
and its main stay mar keted prod uct Velcade (bortezomib), an anticancer proteasome in hib i tor, mar keted
world wide and in Ja pan by John son & John son, which was re ported to re cord block buster sales in 2008.
Ac cord ing to IMS, Velcade was Takeda’s eighth lead ing in ter na tional prod uct in the year end ing Sep tem -
ber 2008 with 2.5% of cor po rate sales, up 40% over the pre vi ous year (fixed-dol lar growth). Velcade
brought Takeda sales of Yen30.3 bil lion in fis cal 2007 (end ing March 2008) and an a lysts at Mor gan Stan -
ley (Au gust 2008) fore cast sales of Yen76.7 bil lion by the year ending March 2013 for Takeda.
The US mar ket saw sales of new con sti pa tion drug Amitiza more than tri pled its sales to $171 mil lion in
the year end ing March 2008 and in the year end ing Sep tem ber 2008, Amitiza be came Takeda’s eighth
lead ing in ter na tional prod uct ac cord ing to IMS with 1.4% mar ket share and growth of 66%.
A po ten tially im por tant prod uct for Takeda is the in som nia treat ment, Rozerem, which was launched on
the US mar ket in 2005 and sales in the year end ing March 2008 jumped 25% to $111 mil lion. How ever,
the US in som nia mar ket is now very crowded and is soon to in clude generics of Sanofi-Aventis’ Ambien
(zolpidem). This may limit the po ten tial for Rozerem in its big gest mar ket which Stilnox/Ambien cur rently
dom i nates with around one-third of this mar ket al though sales are de clin ing and Rozerem is now in fourth
position.
Pharmaceuticals
� Alimentary Tract and Metabolism Agents
ACTOPLUS MET (pioglitazone + metformin), a fixed com bi na tion of pioglitazone and the biguanide,
metformin, was launched for the treat ment of Type 2 di a be tes in the USA in 2005, and is avail able in two
dos ages of 15mg pioglitazone/500mg metformin, and 15mg/850mg, both given once daily. The prod uct
was ap proved in Eu rope in Au gust 2006 and launched in the UK as Competact in 2006. It has since been
launched through out Eu rope and in Oc to ber 2008, Takeda filed for ap proval of Competact in Ja pan. The
prod uct com petes with GlaxoSmithKline’s (UK) Avandamet, which com bines GSK’s Avandia and
metformin. In the year end ing Sep tem ber 2008, Actoplus Met was Takeda’s sixth lead ing prod uct with
3.0% of global cor po rate sales, up 55% over the previous year.
© 2009 IMS Health In cor po rated or its af fil i ates Page 21